Vitrolife AB (0YAY)
London Exchange · UK · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 108.20 |
|---|---|
| 52-week range | 84.75 – 151.60 |
| Return, 1 month / 3 months | +14.0% / +26.0% |
| Return, 1 year / 3 years | −27.0% / −19.8% |
| Trend | Uptrend |
| RSI (14) | 75 |
| Volatility (1 year) | 39.0% |
| Worst drawdown (1 year) | -43.4% |
| Average daily value traded | 0.95M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vitrolife is a Swedish medical technology company based in Gothenburg that supplies products for assisted reproduction. It develops and sells culture media, solutions and laboratory equipment used by fertility clinics and hospital laboratories to handle eggs, sperm and embryos during fertility treatment. Its customers are clinics and laboratory staff who work in reproductive medicine, and the company serves these markets internationally through its own sales organisation and distributors.
On this site Vitrolife AB appears as a stock on the London Exchange (UK), code 0YAY, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vitrolife AB (0YAY) trades on the London Exchange in UK. It last closed at SEK 108.20 on 23 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 2,386 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.0% and over the last three months it rose 26.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 11.2% | ||
| From 52-week high | -28.3% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 26.0% | ||
| 6-month return | -9.3% | ||
| 12-month return, skipping the last month | -35.9% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.4% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.95M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +9.8% |
|---|---|
| 1 month | +14.0% |
| 3 months | +26.0% |
| 6 months | −9.3% |
| 1 year | −27.0% |
| 3 years | −19.8% |
| 5 years | −79.2% |
Signals
| 50-day / 200-day average | 94.14 / 97.29 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 16.12 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Apr 2025 | SEK 1.1000 |
| 26 Apr 2024 | SEK 1.0000 |
| 28 Apr 2023 | SEK 0.8500 |
| 28 Apr 2022 | SEK 0.8000 |
| 29 Apr 2021 | SEK 0.8000 |
| 3 May 2019 | SEK 0.8500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.